Chimeric Therapeutics

Executive Summary

Chimeric Therapeutics is an Australian clinical-stage biotechnology company developing innovative cell therapies for cancer, focusing on autologous CAR-T and allogeneic NK-cell platforms. Its lead programs include first-in-class CDH17 and CLTX CAR-T therapies targeting solid tumors, alongside a best-in-class CORE-NK platform for hematologic malignancies. Currently in Phase 1/2 clinical trials, the company aims to address tumor heterogeneity and immune evasion through novel targets and engineering. With strong preclinical data and initial patient dosing, Chimeric is positioned to contribute to next-generation cellular immunotherapies, though it faces typical early-stage risks. Upcoming catalysts include interim data readouts, potential partnership or financing announcements, and regulatory milestones.

Upcoming Catalysts (preview)

• Q3 2026Interim data from Phase 1/2 trial of CDH17 CAR-T in gastrointestinal cancers20% success
• Q4 2026Initial safety/efficacy data from Phase 1/2 trial of CLTX CAR-T in solid tumors15% success
• Q2 2026Series B financing to support ongoing clinical trials and platform expansion60% success